Press Releases

02.25.2021

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

02.23.2021

U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)

02.22.2021

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.19.2021

Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA

02.18.2021

Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women

02.17.2021

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

02.17.2021

Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma

02.17.2021

Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®

02.12.2021

U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

02.12.2021

Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

02.09.2021

Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries

02.05.2021

Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027